These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38657290)

  • 1. Clinical factors associated with unexpected poor or suboptimal response in Poseidon criteria patients.
    Hochberg A; Dahan MH; Yarali H; Vuong LN; Esteves SC
    Reprod Biomed Online; 2024 Jul; 49(1):103852. PubMed ID: 38657290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of serum AMH and antral follicle count discrepancy for the prediction of ovarian stimulation response in Poseidon criteria patients.
    Hochberg A; Dahan MH; Yarali H; Vuong LN; Esteves SC
    J Assist Reprod Genet; 2024 Mar; 41(3):717-726. PubMed ID: 38358433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individualized FSH dosing based on ovarian reserve testing in women starting IVF/ICSI: a multicentre trial and cost-effectiveness analysis.
    van Tilborg TC; Oudshoorn SC; Eijkemans MJC; Mochtar MH; van Golde RJT; Hoek A; Kuchenbecker WKH; Fleischer K; de Bruin JP; Groen H; van Wely M; Lambalk CB; Laven JSE; Mol BWJ; Broekmans FJM; Torrance HL;
    Hum Reprod; 2017 Dec; 32(12):2485-2495. PubMed ID: 29121350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cumulative delivery rate per aspiration IVF/ICSI cycle in POSEIDON patients: a real-world evidence study of 9073 patients.
    Esteves SC; Yarali H; Vuong LN; Carvalho JF; Özbek İY; Polat M; Le HL; Pham TD; Ho TM; Humaidan P; Alviggi C
    Hum Reprod; 2021 Jul; 36(8):2157-2169. PubMed ID: 34179973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antral follicle count and anti-Müllerian hormone to classify low-prognosis women under the POSEIDON criteria: a classification agreement study of over 9000 patients.
    Esteves SC; Yarali H; Vuong LN; Carvalho JF; Özbek İY; Polat M; Le HL; Pham TD; Ho TM
    Hum Reprod; 2021 May; 36(6):1530-1541. PubMed ID: 33822057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of 'normal' early follicular FSH concentrations with unexpected poor or suboptimal response when ovarian reserve markers are reassuring: a retrospective cohort study.
    Del Gallego R; Lawrenz B; Ata B; Kalafat E; Melado L; Elkhatib I; Fatemi H
    Reprod Biomed Online; 2024 Mar; 48(3):103701. PubMed ID: 38309124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Ovarian Reserve Tests and Age in the Prediction of Poor Ovarian Response to Controlled Ovarian Stimulation-A Real-World Data Analysis of 89,002 Patients.
    Wang X; Jin L; Mao YD; Shi JZ; Huang R; Jiang YN; Zhang CL; Liang XY
    Front Endocrinol (Lausanne); 2021; 12():702061. PubMed ID: 34526967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization.
    Nardo LG; Gelbaya TA; Wilkinson H; Roberts SA; Yates A; Pemberton P; Laing I
    Fertil Steril; 2009 Nov; 92(5):1586-93. PubMed ID: 18930213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response-a randomized, controlled trial.
    Magnusson Å; Nilsson L; Oleröd G; Thurin-Kjellberg A; Bergh C
    Hum Reprod; 2017 Apr; 32(4):811-819. PubMed ID: 28175316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-Mullerian Hormone (AMH) levels in serum and follicular fluid as predictors of ovarian response in stimulated (IVF and ICSI) cycles.
    Tolikas A; Tsakos E; Gerou S; Prapas Y; Loufopoulos A
    Hum Fertil (Camb); 2011 Dec; 14(4):246-53. PubMed ID: 22088130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI).
    Lensen SF; Wilkinson J; Leijdekkers JA; La Marca A; Mol BWJ; Marjoribanks J; Torrance H; Broekmans FJ
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD012693. PubMed ID: 29388198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Müllerian hormone versus antral follicle count for defining the starting dose of FSH.
    Lan VT; Linh NK; Tuong HM; Wong PC; Howles CM
    Reprod Biomed Online; 2013 Oct; 27(4):390-9. PubMed ID: 23953069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of three COS protocols and predictability of AMH and AFC in women with discordant ovarian reserve markers: a retrospective study on 19,239 patients.
    Guo Y; Jiang H; Hu S; Liu S; Li F; Jin L
    J Ovarian Res; 2021 Aug; 14(1):111. PubMed ID: 34454544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of antral follicle count and serum anti-Müllerian hormone: Which is better for live birth prediction in patients aged over 40 with their first IVF treatment?
    Lee Y; Kim TH; Park JK; Eum JH; Lee HJ; Kim J; Lyu SW; Kim YS; Lee WS; Yoon TK
    Eur J Obstet Gynecol Reprod Biol; 2018 Feb; 221():151-155. PubMed ID: 29306180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian response is associated with anogenital distance in patients undergoing controlled ovarian stimulation for IVF.
    Fabregues F; González-Foruria I; Peñarrubia J; Carmona F
    Hum Reprod; 2018 Sep; 33(9):1696-1704. PubMed ID: 30016431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI).
    Ngwenya O; Lensen SF; Vail A; Mol BWJ; Broekmans FJ; Wilkinson J
    Cochrane Database Syst Rev; 2024 Jan; 1(1):CD012693. PubMed ID: 38174816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antral follicle count determines poor ovarian response better than anti-Müllerian hormone but age is the only predictor for live birth in in vitro fertilization cycles.
    Mutlu MF; Erdem M; Erdem A; Yildiz S; Mutlu I; Arisoy O; Oktem M
    J Assist Reprod Genet; 2013 Jun; 30(5):657-65. PubMed ID: 23508679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cumulative live birth rates in low-prognosis women.
    Leijdekkers JA; Eijkemans MJC; van Tilborg TC; Oudshoorn SC; van Golde RJT; Hoek A; Lambalk CB; de Bruin JP; Fleischer K; Mochtar MH; Kuchenbecker WKH; Laven JSE; Mol BWJ; Torrance HL; Broekmans FJM;
    Hum Reprod; 2019 Jun; 34(6):1030-1041. PubMed ID: 31125412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: The predicted poor responder.
    van Tilborg TC; Torrance HL; Oudshoorn SC; Eijkemans MJC; Koks CAM; Verhoeve HR; Nap AW; Scheffer GJ; Manger AP; Schoot BC; Sluijmer AV; Verhoeff A; Groen H; Laven JSE; Mol BWJ; Broekmans FJM;
    Hum Reprod; 2017 Dec; 32(12):2496-2505. PubMed ID: 29121326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of anti-müllerian hormone, follicle-stimulating hormone and antral follicle count on the outcome of ovarian stimulation in women following GnRH-antagonist protocol for IVF/ET.
    Tsakos E; Tolikas A; Daniilidis A; Asimakopoulos B
    Arch Gynecol Obstet; 2014 Dec; 290(6):1249-53. PubMed ID: 25001569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.